A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events

References

• Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-46
   Google Scholar
• National MS Society. Comparing the disease-modifying drugs. Available at: http://www.nationalmssociety.org/Brochures-Comparing.asp [Last accessed 21 August 2006]
   Google Scholar
• Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000;4: CD001331
   PubMedGoogle Scholar
• IFNB multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
   Google Scholar
• Jacobs L, Cookfair D, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998;50:701-8
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis. Lancet 2001;357:1576-82
   PubMed Web of Science ®Google Scholar
• Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9
   PubMed Web of Science ®Google Scholar
• Hartung H-P, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-25
   PubMed Web of Science ®Google Scholar
• Fox E. Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther 2006;28:461-74
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239-47
   PubMed Web of Science ®Google Scholar
• Bergh FT, Kumpfel T, Schumann E, et al. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis—reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurology 2006;6:19-28
   PubMed Web of Science ®Google Scholar
• Smith DR, Weinstock-Guttman B, Cohen JA, et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta. Mult Scler 2005;11:573-82
   PubMed Web of Science ®Google Scholar
• La Mantia L, D’Amico D, Rigamonti A, et al. Interferon treatment may trigger primary headaches in multiple sclerosis patients. Mult Scler 2006;12:476-80
   PubMed Web of Science ®Google Scholar
• Goodkin DE, Rudick RA, Medendorp SV, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995;37:30-40
   PubMed Web of Science ®Google Scholar
• Pulicken M, Bash CN, Costello K, et al. Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination in multiple sclerosis. Mult Scler 2005;11:169-74
   PubMed Web of Science ®Google Scholar
• British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet 1988;2:179-83
   PubMed Web of Science ®Google Scholar
• Markovic-Plese S, Bielekova B, Kadom N, et al. Longitudinal MRI study. The effects of azathioprine in MS patients refractory to interferon β-1b. Neurology 2003;60:1849-51
   Google Scholar
• Filippi M, Rocca MA, Pagani E, et al. European study on intravenous immunoglobulin in multiple sclerosis. Arch Neurol 2004;61:1409-12
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998;50:1273-81
   PubMed Web of Science ®Google Scholar
• Fazekas F, Sorensen PS, Filippi M, et al. MRI results from the European study on intravenous immunoglobulin in secondary progressive multiple sclerosis (ESIMS). Mult Scler 2005;11:433-40
   PubMed Web of Science ®Google Scholar
• Hommes OR, Sorensen PS, Fazekas F, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004;364:1149-56
   PubMed Web of Science ®Google Scholar
• Vollmer TL, Hadjimicahel O, Preiningerova J, et al. Disability and treatment patterns of multiple sclerosis patients in United States: a comparison of veterans and non-veterans. J Rehabil Res Dev 2002;39:163-74
   PubMed Web of Science ®Google Scholar
• Lo AC, Hadjimichael O, Vollmer TL. Treatment patterns of multiple sclerosis patients: a comparison of veterans and non-veterans using the NARCOMS registry. Mult Scler 2005;11:33-40
   PubMed Web of Science ®Google Scholar
• Daugherty KK, Butler JS, Mattingly M, et al. Factors leading patients to discontinue multiple sclerosis therapies. J Am Pharm Assoc 2005;45:371-5
   Google Scholar
• Fraser C, Morgante L, Hadjimichael O, et al. A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. J Neurosci Nurs 2004;36:120-9
   PubMedGoogle Scholar
• Hadjimichael O, Vollmer TL. Adherence to injection therapy in multiple sclerosis: patients survey. Neurology 1999;52:A549
   Google Scholar
• Tremlett HL, Oger J. Interrupted therapy. Stopping and switching of the β-interferons prescribed for MS. Neurology 2003;61:551-4
   Google Scholar
• Mohr DC, Boudewyn AC, Likosky W, et al. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 2001;23:125-32
   PubMed Web of Science ®Google Scholar
• Low A, Markowitz M. Predictors of response to highly active antiretroviral therapy. AIDS Read 2006;168:425-8, 430
   Google Scholar
• World Health Organization. Adherence to long-term therapies. Evidence for action. 2003. Available at: http://www.who.int/chronic_conditions/en/adherence_report.pdf [Last accessed 21 August 2006]
   Google Scholar
• Treadaway K, Brannon K, Morrison A, et al. Factors that influence adherence with disease-modifying therapy in multiple sclerosis [P01.071]. Presented at: 58th Annual Meeting of the American Academy of Neurology, April 1-8, 2006; San Diego, CA
   Google Scholar
• Holland N, Wiesel P, Cavallo P, et al. Adherence to disease-modifying therapy in multiple sclerosis: Part I. Rehab Nurs 2001;26:172-6
   PubMedGoogle Scholar
• Becker MH. The health belief model and personal health behavior. Health Educ Monogr 1974;2:324-508
   Google Scholar
• Holland N, Wiesel P, Cavallo P, et al. Adherence to disease-modifying therapy in multiple sclerosis: Part II. Rehab Nurs 2001;26:221-6
   PubMedGoogle Scholar
• Prochaska JO, DiClemente CC. Stages of change in the modification of problem behaviors. In: Hersen M, Eisler RM, Miller PM, eds. Progress in Behavior Modification. Sycamore, IL: Sycamore Publishing Co., 1992
   Google Scholar
• Runmarker B, Anderson O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116:117-34
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Wende KE, Brownscheidle CM, et al. A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Mult Scler 1999;5:369-70
   PubMed Web of Science ®Google Scholar
• Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006;66:172-7
   PubMed Web of Science ®Google Scholar
• DeSousa EA, Albert RH, Kalman B. Cognitive impairments in multiple sclerosis: a review. Am J Alzheimer's Dis Other Dement 2002;17:23-9
   PubMedGoogle Scholar
• Rao SM. Cognitive function in patients with multiple sclerosis: impairment and treatment. Int J MS Care 2004;1:9-22
   Google Scholar
• McIntosh-Michaelis SA, Roberts MH, Wilkinson SM, et al. The prevalence of cognitive impairment in a community survey of multiple sclerosis. Br J Clin Psychol 1991;30:333-48
   PubMed Web of Science ®Google Scholar
• PRISMS Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-36
   PubMed Web of Science ®Google Scholar
• Johnson JP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-76
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Wolinsky J; the European/Canadian Copaxone Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing-remitting multiple sclerosis. Ann Neurol 2001;49:290-7
   PubMed Web of Science ®Google Scholar
• Munschauer FE, Kinkel RP. Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Ther 1997;19:883-93
   PubMed Web of Science ®Google Scholar
• O’Connell D. Is it an MS attack—or not? National MS Society: Inside MS. 2004. Available at: http://www.nationalmssociety.org/IMSJuly04-MSAttackOrNot.asp [Last accessed 14 September 2006]
   Google Scholar
• Runkel L, Meier W, Blake R, et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β). Pharm Res 1998;15:641-9
   PubMed Web of Science ®Google Scholar
• Avonex [package insert]. Cambridge, MA: Biogen Idec, Inc.; 2006
   Google Scholar
• Rebif [package insert]. Rockland, MA: Serono, Inc.; 2005
   Google Scholar
• Betaseron [package insert]. Montville, NJ: Berlex Laboratories; 2003
   Google Scholar
• Bayas A, Rieckmann P. Managing the adverse effects of interferon-β therapy in multiple sclerosis. Drug Safety 2000;22:149-59
   PubMed Web of Science ®Google Scholar
• Frohman EM, Brannon K, Alexander S, et al. Disease-modifying agent-related skin reactions in multiple sclerosis: prevention, assessment, and management. Mult Scler 2004;10:302-7
   PubMed Web of Science ®Google Scholar
• Sandberg-Wollheim M, Bever C, Carter J, et al. Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study. J Neurol 2005;2:8-13
   Google Scholar
• Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN). Lancet 2002;359:1453-60
   PubMed Web of Science ®Google Scholar
• IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85
   PubMed Web of Science ®Google Scholar
• Saida T, Tashiro K, Itoyama Y, et al. Interferon beta-1b is effective in Japanese RRMS patients. A randomized, multicenter study. Neurology 2005;64:621-30
   PubMed Web of Science ®Google Scholar
• Sheremata WA, Taylor JR, Elgart GW. Severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b. N Engl J Med 1995;332:1584
   PubMed Web of Science ®Google Scholar
• Inafuku H, Khan MAK, Nagata T, Nonaka S, et al. Cutaneous ulcerations following subcutaneous interferon β injection to a patient with multiple sclerosis. J Dermatol 2004;31:671-7
   PubMed Web of Science ®Google Scholar
• Feldmann R, Low-Weiser H, Duschet P, et al. Necrotizing cutaneous lesions caused by interferon beta injections in a patient with multiple sclerosis. Dermatology 1997;195:52-3
   PubMed Web of Science ®Google Scholar
• Webster GF, Knobler RL, Lublin FD, et al. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol 1996;34:365-7
   PubMed Web of Science ®Google Scholar
• Galetta SL, Markowitz C. US FDA-approved disease-modifying treatments for multiple sclerosis. Review of adverse effect profiles. CNS Drugs 2005;19:1-14
   Google Scholar
• Frohman E, Phillips T, Kokel K, et al. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist 2002;8:227-36
   PubMed Web of Science ®Google Scholar
• Avonex [medication guide]. Cambridge, MA: Biogen Idec, Inc.; 2006
   Google Scholar
• Rebif [medication guide]. Rockland, MA: Serono, Inc.; 2005
   Google Scholar
• Tornatore C, Bartlett D. Tolerability of interferon beta-1b (Betaferon®/Betaseron®) can be significantly improved using both interferon-free needle and automated injection techniques. J Neurol 2002;249:I/205
   Google Scholar
• Mikol D, Lopez-Bresnahan M, Taraskiewicz S, et al. On behalf of the Rebiject Study Group. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif®) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult Scler 2005;11:585-91
   PubMedGoogle Scholar
• Rio J, Nos C, Bonaventura I, et al. Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial. Neurology 2004;63:525-8
   PubMed Web of Science ®Google Scholar
• Rees J, Haas J, Gabriel K, et al. Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX®) therapy. Mult Scler 2002;8:15-8
   PubMed Web of Science ®Google Scholar
• Rice GP, Ebers GC, Lublin FD, et al. Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS. Neurology 1999;52:1893-5
   PubMed Web of Science ®Google Scholar
• Wroe SJ. Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis. J Int Med Res 2005;33:309-18
   PubMed Web of Science ®Google Scholar
• Brandes D, Bigley GK, Warth J, et al. (S08) Flu-like symptoms in MS patients on IM IFNβ-1a therapy: management strategies. Poster presented at: Navigating the World of Multiple Sclerosis (CMSC); June 1-5, 2005; Orlando, FL
   Google Scholar
• Patten SB, Fridhandler S, Beck CA, et al. Depressive symptoms in a treated multiple sclerosis cohort. Mult Scler 2003;9:616-20
   PubMed Web of Science ®Google Scholar
• Patten SB, Francis G, Metz LM, et al. The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler 2005;11:175-81
   PubMed Web of Science ®Google Scholar
• Galeazzi GM, Ferrari S, Giaroli G, et al. Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy. Neurol Sci 2005;26:255-62
   PubMed Web of Science ®Google Scholar
• Sadovnick AD, Remick RA, Allen J, et al. Depression and multiple sclerosis. Neurology 1996;46:628-32
   PubMed Web of Science ®Google Scholar
• Zephir H, De Seze J, Stojkovic T, et al. Multiple sclerosis and depression: influence of interferon β therapy. Mult Scler 2003;9:284-8
   PubMed Web of Science ®Google Scholar
• Feinstein A, O’Connor P, Feinstein K. Multiple sclerosis, interferon beta-1b and depression. A prospective investigation. J Neurol 2002;249:815-20
   Google Scholar
• Mohr DC, Goodkin DE, Likosky W, et al. Treatment of depression improved adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997;54:531-3
   PubMed Web of Science ®Google Scholar
• Durelli L, Ferrero B, Oggero A, et al. Liver and thyroid function and autoimmunity during interferon-β1b treatment for MS. Neurology 2001;57:1363-70
   PubMed Web of Science ®Google Scholar
• Tremlett HL, Yoshida EM, Oger J. Liver injury associated with the β-interferons for MS. A comparison between the three products. Neurology 2004;62:628-31
   Google Scholar
• Lublin FD, Whitaker JN, Eidelman BH, et al. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996;46:12-8
   PubMed Web of Science ®Google Scholar
• Rieckmann P, Weber F, Gunther A, et al. The phosphodiesterase inhibitor pentoxifylline reduces early side effects of interferon-β1b treatment in patients with multiple sclerosis. Neurology 1996;47:604
   PubMed Web of Science ®Google Scholar
• D’Amico D, La Mantia L, Rigamonti A, et al. Prevalence of primary headaches in people with multiple sclerosis. Cephalalgia 2004;24:980-4
   PubMed Web of Science ®Google Scholar
• Pollmann W, Erasmus L-P, Feneberg W, et al. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS. Neurology 2006;66:275-7
   PubMed Web of Science ®Google Scholar
• Khromov A, Segal M, Nissinofff J, et al. Migraines linked to interferon β treatment of multiple sclerosis. Am J Phys Med Rehabil 2005;84:644-7
   PubMed Web of Science ®Google Scholar
• Weber F, Polak T, Gunther A, et al. Synergistic immunomodulatory effects of interferon-β1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Ann Neurol 1998;44:27-34
   PubMed Web of Science ®Google Scholar
• Neve HJ, Bhatti WA, Soulsby C, et al. Reversal of hair loss following vertical gastroplasty when treated with zinc sulfate. Obes Surg 1996;6:63-5
   PubMed Web of Science ®Google Scholar
• Kreiss Y, Cohen O, Pras E, et al. Subacute thyroiditis in a patient with MS treated with interferon beta-1a. Neurology 1999;53:1606
   PubMed Web of Science ®Google Scholar
• Schwid SR, Goodman AD, Mattson DH. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b. Arch Neurol 1997;54:1169-90
   PubMed Web of Science ®Google Scholar
• McDonald ND, Pender MP. Autoimmune hypothyroidism associated with interferon beta-1b treatment in two patients with multiple sclerosis. Aust N Z J Med 2000;30:278-9
   PubMedGoogle Scholar
• Durelli L, Ferrero B, Oggero A, et al. Autoimmune events during interferon beta-1b treatment for multiple sclerosis. J Neurol Sci 1999;162:74-83
   PubMed Web of Science ®Google Scholar
• Monzani F, Caraccio N, Dardano A, et al. Thyroid autoimmunity and dysfunction associated with type 1 interferon therapy. Clin Exp Med 2004;3:199-210
   PubMed Web of Science ®Google Scholar
• Petek-Balci B, Yayla V, Ozer F. Multiple sclerosis and Hashimoto thyroiditis. Two cases. Neurologist 2005;11:301-4
   PubMed Web of Science ®Google Scholar
• Russo R, Tenembaum S, Moreno MJ, et al. Interferon-β1a–induced juvenile chronic arthritis in a genetically predisposed young patient with multiple sclerosis: comment on the case report by Levesque. Arthritis Rheum 2000;43:1190
   PubMed Web of Science ®Google Scholar
• Altintas A, Alici Y, Melikoglu M, et al. Arthritis during interferon beta-1b treatment in multiple sclerosis. Mult Scler 2002;8:534-6
   PubMed Web of Science ®Google Scholar
• Strueby L, Nair B, Kirk A, et al. Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta. Scand J Rheumatol 2005;34:485-8
   PubMed Web of Science ®Google Scholar
• Nousari HC, Kimyai-asadi A, Tausk FA. Subacute cutaneous lupus erythematosus associated with interferon beta-1a. Lancet 1998;352:1825-6
   PubMed Web of Science ®Google Scholar
• Dionisiotis J, Zoukos Y, Thomaides T. Development of myasthenia gravis in two patients with multiple sclerosis following interferon B treatment. J Neurol Neurosurg Psychiatry 2004;75:1079
   PubMed Web of Science ®Google Scholar
• Blake G, Murphy S. Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment. Neurology 1997;49:1747-8
   PubMed Web of Science ®Google Scholar
• De Seze J, Canva-Delcambre V, Fajardy I, et al. Autoimmune hepatitis and multiple sclerosis: a coincidental association? Mult Scler 2005;11:691-3
   PubMed Web of Science ®Google Scholar
• Pulicken M, Koteish A, DeBusk K, et al. Unmasking of autoimmune hepatitis in a patient with MS following interferon beta therapy. Neurology 2006;66:1954-5
   PubMed Web of Science ®Google Scholar
• Linden D. Severe Raynaud's phenomenon associated with interferon-B treatment for multiple sclerosis. Lancet 1998;352:878-9
   PubMed Web of Science ®Google Scholar
• Cruz RD. [Severe Raynaud's phenomenon associated with interferon-beta therapy for multiple sclerosis: case report.] Arq Neuropsiquiatr 2000;58:556-9 [article in Portuguese]
   Google Scholar
• Tanvetyanon T, Stadtmauer EA, Kerson LA. Concurrent administration of interferon alfa-2b and beta-1a. Ann Pharmacother 2003;37:77-9
   PubMed Web of Science ®Google Scholar
• Batay F, AlMefty O. Growth dynamics of meningiomas in patients with multiple sclerosis treated with interferon: report of two cases. Acta Neurochir Wien 2002;144:365-8
   PubMed Web of Science ®Google Scholar
• Sega S, Horvat A, Popovic M. Anaplastic oligodendroglioma and gliomatosis type 2 in interferon-β treated multiple sclerosis patients. Report of two cases. Clin Neurol Neurosurg 2006;108:259-65
   PubMed Web of Science ®Google Scholar
• Drevelegas A, Xinou E, Karacostas D, et al. Meningioma growth and interferon beta-1b treated multiple sclerosis: coincidence or relationship? Neuroradiology 2005;47:516-19
   PubMed Web of Science ®Google Scholar
• Case Records of the Massachusetts General Hospital. Case 34-2001. N Engl J Med 2001;345:1409-15
   PubMed Web of Science ®Google Scholar
• Teitelbaum D, Meshorer A, Hirshfeld T, et al. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971;1:242-8
   PubMed Web of Science ®Google Scholar
• Copaxone [package insert]. Kansas City, MO: Teva Neuroscience, Inc.; 2006
   Google Scholar
• Edgar CM, Brunet DG, Fenton P, et al. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Can J Neurol Sci 2004;31:58-63
   PubMed Web of Science ®Google Scholar
• Drago F, Brusati C, Mancardi G, et al. Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis. Arch Dermatol 1999;135:1277-8
   PubMed Web of Science ®Google Scholar
• Mancardi GL, Murialdo A, Drago F, et al. Localized lipoatrophy after prolonged treatment with copolymer 1. J Neurol 2000;247:220-1
   PubMed Web of Science ®Google Scholar
• Hwang L, Orengo I. Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis. Cutis 2001;68:287-8
   PubMed Web of Science ®Google Scholar
• Soos N, Shakery K, Mrowietz U. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis. Am J Clin Dermatol 2004;5:357-9
   PubMed Web of Science ®Google Scholar
• Windhagen A, Maniak S, Marckmann S, et al. Lymphadenopathy in patients with multiple sclerosis undergoing treatment with glatiramer acetate. J Neurol Neurosurg Psychiatry 2001;70:415-6
   PubMed Web of Science ®Google Scholar
• Flechter S, Kott E, Steiner-Birmanns B, et al. Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration. Clin Neuropharm 2002;25:11-5
   PubMed Web of Science ®Google Scholar
• Flechter S, Vardi J, Pollak L, et al. Comparison of glatiramer acetate (Copaxone®) and interferon β-1b (Betaferon®) in multiple sclerosis patients: an open-label 2-year follow-up. J Neurol Sci 2002;197:51-5
   PubMed Web of Science ®Google Scholar
• Beiske AG, Myrh K-M. Lipoatrophy: a non-reversible complication of subcutaneous interferon-beta 1a treatment of multiple sclerosis. J Neurol 2006;253:377-8
   PubMed Web of Science ®Google Scholar
• Kauffman CL, Sina B, Costello K, et al. Cutaneous reactions to interferon beta-1b (Betaseron) in multiple sclerosis patients, a clinical and pathological study [abstract]. Am J Dermatopathology 1997;19:512
   Google Scholar
• Ziemssen T, Neuhaus O, Hohlfeld R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Safety 2001;24:979-90
   PubMed Web of Science ®Google Scholar
• Tysabri (natalizumab) [package insert]. Cambridge, MA: Biogen Idec, Inc., 2006
   Google Scholar
• Langer-Gould A, Atlas SW, Bollen AW, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-81
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-Demasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-74
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-8
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. Natalizumab (marketed as Tysabri) information. Available at: http://www.fda.gov/cder/drug/infopage/natalizumab/default.htm [Last accessed 11 September 2006]
   Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23
   PubMed Web of Science ®Google Scholar
• Perini P, Facchinetti A, Bulian P, et al. Interferon-beta (IFN-β) antibodies in interferon-β1a- and interferon-β1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-β immunogenicity in vivo. Eur Cytokine Netw 2001;12:56-61
   Google Scholar
• Barnes D, Hughes RAC, Morris RW, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997;349:902-6
   PubMed Web of Science ®Google Scholar
• Caldwell JR, Furst DE. The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis. Semin Arthritis Rheum 1991;21:1-11
   PubMed Web of Science ®Google Scholar
• Durelli L, Cocito D, Riccio A, et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 1986;36:238-43
   PubMed Web of Science ®Google Scholar
• Hillen HFP, Breed WPM, Botman CJ. Scalp cooling by cold air for the prevention of chemotherapy-induced alopecia. Neth J Med 1990;37:231-5
   PubMed Web of Science ®Google Scholar
• Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002;59:909-13
   PubMed Web of Science ®Google Scholar
• Ghalie RG, Mauch E, Edan G, et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002;8:441-5
   PubMed Web of Science ®Google Scholar
• Bernitsas E, Wei W, Mikol D. Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. Ann Neurol 2006;59:206-9
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Text Revision. DSM-IV-TR. Washington, DC: American Psychiatric Publishing, 2000
   Google Scholar
• Cox D, Mohr DC. Managing difficulties with adherence to injectable medications due to blood, injection, and injury phobia and self-injection anxiety. Am J Drug Delivery 2003;1:215-21
   Google Scholar
• Pohl D, Rostasy K, Hanefeld F. Multiple sclerosis in childhood and adolescence: treatment with subcutaneous interferon-beta-1a. Poster presented at: 57th Annual Meeting of the American Academy of Neurology; April 9-16, 2005; Miami, FL, USA
   Google Scholar
• Mohr DC, Cox D, Merluzzi N. Self-injection anxiety training: a treatment for patients unable to self-inject injectable medications. Mult Scler 2005;11:182-5
   PubMed Web of Science ®Google Scholar
• Pfohl DC. A multiple sclerosis (MS) center injection training program. Axon 1997;19:29-33
   PubMedGoogle Scholar
• National MS Society. Medicare prescription drug coverage. 2006. Available at: http://www.nationalmssociety.org/medicare_benefit.asp/2/4 [Last accessed 21 August 2006]
   Google Scholar
• National MS Society. Disease management consensus statement. 2006. Available at: http://www.nationalmssociety.org/pdf/sourcebook/consensus_summary.pdf [Last accessed 21 August 2006]
   Google Scholar
• La Mantia L, Milanese C, Mascoli N, et al. Cyclophosphamide for multiple sclerosis. Cochrane Database Syst Rev 2006;24: CD002819
   Google Scholar
• Vittorio CC, Ricci KT. Monitoring for major side effects of systemic drugs in dermatology. Dermatol Nurs 1996;8:247-59
   PubMedGoogle Scholar
• Taylor L, Hughes RAC, McPherson K. The risk of cancer from azathioprine as a treatment for multiple sclerosis. Eur J Neurol 2004;11:141
   PubMed Web of Science ®Google Scholar
• Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998;129:716-8
   PubMed Web of Science ®Google Scholar
• Zaidan R, Moallem MA, Wani BA, et al. Thrombosis complicating high dose intravenous immunoglobulin: report of three cases and review of the literature. Eur J Neurol 2003;10:367-72
   PubMed Web of Science ®Google Scholar